The DOI matches its Crossref record.
RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION
Abstract
The plasma concentration of aldosterone was followed in seven hypertensive patients before and during long-term angiotensin II suppression with the orally active angiotensin-I-converting-enzyme inhibitor, captopril. The plasma concentration of aldosterone decreased initially from 74 to 21 pg/ml (P less than 0.05) after 1 month of administration of captopril. Thereafter the plasma concentration of aldosterone began to rise and after 1 year reached a level of 165 pg/ml. During long-term captopril therapy the plasma renin activity remained increased and the plasma angiotensin II concentration suppressed. The mechanism responsible for the late rise of the plasma concentration of aldosterone during long-term angiotensin II suppression with captopril remains to be elucidated. A sizeable and lasting hypotensive effect was observed in all patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Experimental evidence suggests that RAS blockade leads to incomplete suppression of serum aldosterone levels (aldosterone escape phenomenon), offering an opportunity to consider additional treatment options to lower residual albuminuria and ameliorate kidney fi brosis.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [154]
Citations
Cites
Still being checked.
Cited by
Sorted by citations
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. J. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,595
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 500
(1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00465-1 · Cited by 493
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 473
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0575 · Cited by 426
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 386
Tsutamoto, T., Wada, A., Maeda, K., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Sawaki, M., Fujii, M., Matsumoto, T., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01116-0 · Cited by 367
Pitt, B., Williams, G. H., Remme, W. J., Martínez, F., Lopez-Sendon, J. L., Zannad, F. M., Neaton, J. D., Roniker, B., Hurley, S., Burns, D. M., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Latini, R. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.10.030 · Cited by 344
Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Zuckerman, A. L., & Stier, C. T. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.232 · Cited by 310
Parving, H. ‐., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M. M., Weissbach, N., Xiang, Z., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn721 · Cited by 305
Cleland, J. G. F., Dargie, H. J., Ball, S. G., Gillen, G., Hodsman, G. P., Morton, J. J., East, B. W., Robertson, I., Ford, I., & Robertson, J. I. S. (1985) · Heart · doi:10.1136/hrt.54.3.305 · Cited by 277
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease
Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04750908 · Cited by 270
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
Aldosterone antagonists for preventing the progression of chronic kidney disease
Bolignano, D., Palmer, S. C., Navaneethan, S. D., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub3 · Cited by 250
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
Struthers, A. D. (1996) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(96)80009-1 · Cited by 228
Suzuki, G., Morita, H., Mishima, T., Sharov, V. G., Todor, A. V., Tanhehco, E. J., Rudolph, A. E., McMahon, E. G., Goldstein, S., & Sabbah, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000039104.56479.42 · Cited by 214
Pitt, B. (1995) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00877755 · Cited by 207
The role of spironolactone in the treatment of patients with refractory hypertension
Ouzan, J. M., Perault, C., Lincoff, A. M., Carre, E., & Mertès, P. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02342-1 · Cited by 203
Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180
Aldosterone antagonists for preventing the progression of chronic kidney disease
Navaneethan, S. D., Nigwekar, S. U., & Strippoli, G. F. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004 · Cited by 167
Yee, K.-M., Pringle, S. D., & Struthers, A. D. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01243-8 · Cited by 160
Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
Segall, L., Nistor, I., & Covic, A. C. (2014) · BioMed Research International · doi:10.1155/2014/937398 · Cited by 164
Brown, N. J. (2003) · Circulation · doi:10.1161/01.cir.0000071081.35693.9a · Cited by 159
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
Epstein, M. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80115-3 · Cited by 157
Bauersachs, J. K., Heck, M., Fraccarollo, D., Hildemann, S. K., Ertl, G., Wehling, M., & Christ, M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01729-6 · Cited by 151
Sato, A., & Saruta, T. (2001) · Journal of International Medical Research · doi:10.1177/147323000102900103 · Cited by 148
Furosemide and the progression of left ventricular dysfunction in experimental heart failure
McCurley, J. M., Hanlon, S. U., Wei, S.-K., Wedam, E. F., Michalski, M., & Haigney, M. C. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.04.059 · Cited by 143
Duprez, D. A., Bauwens, F. R., De Buyzere, M. L., De Backer, T. L., Kaufman, J. M., Van Hoecke, J., Vermeulen, A., & Clement, D. L. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90240-d · Cited by 139
Tandon, P., Abraldeṣ, J. G., Berzigotti, A., García‐Pagán, J. C., & Bosch, J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.013 · Cited by 134
Katayama, S., Yamada, D., Nakayama, M., Yamada, T., Myoishi, M., Kato, M. C., Nowack, C., Kolkhof, P., & Yamasaki, Y. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.021 · Cited by 133
Ramires, F. J. A., Mansur, A. D. P., Coelho, O. R., Maranhão, M., Gruppi, C. J., Mady, C., & Ramires, J. A. F. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00729-3 · Cited by 132
Naruse, M., Tanabe, A., Sato, A., Takagi, S., Tsuchiya, K., Imaki, T., & Takano, K. (2002) · Hypertension · doi:10.1161/01.hyp.0000022606.52221.2f · Cited by 129
Aldosterone as a Mediator in Cardiovascular Injury
Stier, C. T., Chander, P. N., & Rocha, R. (2002) · Cardiology in Review · doi:10.1097/00045415-200203000-00008 · Cited by 128
Aldosterone and Myocardial Fibrosis in Heart Failure
Brilla, C. G. (2000) · Herz · doi:10.1007/s000590050024 · Cited by 135
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy
Sato, A. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)00913-0 · Cited by 129
Beta-Blocker Therapy for Cardiac Dysfunction in Patients With Muscular Dystrophy
Kajimoto, H., Ishigaki, K., Okumura, K., Tomimatsu, H., Nakazawa, M., Saito, K., Ōsawa, M., & Nakanishi, T. (2006) · Circulation Journal · doi:10.1253/circj.70.991 · Cited by 117
Julian, B. A., & Novák, J. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200403000-00005 · Cited by 112
Aldosterone Blockade: An Emerging Strategy for Abrogating Progressive Renal Disease
Epstein, M. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.038 · Cited by 112
Aldosterone and antialdosterone therapy in congestive heart failure
Weber, K. T., & Villarreal, D. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90238-8 · Cited by 108
Tsunoda, K., Abe, K., Hagino, T., Omata, K., Misawa, S., Imai, Y., & YOSHINAGA, K. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.1.28 · Cited by 106
Aldosterone-receptor antagonism in hypertension
Jansen, P. M., Danser, A. J., Imholz, B. P. M., & van den Meiracker, A. H. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832810ed · Cited by 92
Pitt, B., Ferreira, J. P., & Zannad, F. M. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw016 · Cited by 90
Epstein, M. (2001) · Journal of Hypertension · doi:10.1097/00004872-200105000-00001 · Cited by 87
Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases
Patel, B. M., & Mehta, A. A. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.034 · Cited by 87
Cohn, J. N., Anand, I. S., Latini, R., Masson, S., Chiang, Y., & Glazer, R. D. (2003) · Circulation · doi:10.1161/01.cir.0000091234.45664.62 · Cited by 87
Aldosterone: Cardiovascular assault
Struthers, A. D. (2002) · American Heart Journal · doi:10.1067/mhj.2002.129969 · Cited by 84
Liu, L. C. Y., Schutte, E., Gansevoort, R. T., van der Meer, P., & Voors, A. A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1059819 · Cited by 85
Young, M. J., & Funder, J. W. (2002) · Journal of Hypertension · doi:10.1097/00004872-200208000-00002 · Cited by 84
Álvarez-Álvarez, B., Abad-Cardiel, M., Fernández‐Cruz, A., & Claros, N. M. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833d4c99 · Cited by 83
Young, M. J., & Funder, J. W. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00270-8 · Cited by 81
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Newman, J. D., O’Meara, E., Böhm, M., Savarese, G., Kelly, P. R., Vardeny, O., Allen, L. A., Lancellotti, P., Gottlieb, S. S., Samad, Z. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.033 · Cited by 87
Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys
Jaggi, J. S., Seshan, S. V., McDevitt, M. R., Sgouros, G., Hyjek, E. M., & Scheinberg, D. A. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.11.036 · Cited by 78
Queisser, N., & Schupp, N. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.011 · Cited by 79
Johnson, A. K., & Grippo, A. J. (2006) · PubMed · Cited by 75
Edelmann, F., Schmidt, A. G., Gelbrich, G., Binder, L., Herrmann‐Lingen, C., Halle, M., Hasenfuss, G. P., Wachter, R., & Pieske, B. M. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq087 · Cited by 74
Hostetter, T. H., Rosenberg, M. E., Ibrahim, H. N., & Juknevicius, I. (2001) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200101000-00016 · Cited by 72
Brown, J., de Boer, I. H., Robinson-Cohen, C., Siscovick, D. S., Kestenbaum, B., Allison, M., & Vaidya, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3949 · Cited by 71
Schäfer, A. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00333-x · Cited by 70
Multiple Endocrine Regulation by Bone Morphogenetic Protein System
Otsuka, F. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-310 · Cited by 69
The effect of low-dose spironolactone on resistant hypertension
Engbæk, M., Hjerrild, M., Hallas, J., & Jacobsen, I. A. (2010) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2010.10.001 · Cited by 68
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157
Sato, A., Hayashi, M., & Saruta, T. (2002) · Hypertension Research · doi:10.1291/hypres.25.837 · Cited by 65
Cook, C. S., Berry, L., Kim, D. H., Burton, E. G., Hribar, J. D., & Zhang, L. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1344 · Cited by 63
The role of the AT2 receptor in hypertension
Siragy, H. M. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)00274-0 · Cited by 61
Sato, A., Suzuki, Y., & Saruta, T. (1999) · Hypertension Research · doi:10.1291/hypres.22.17 · Cited by 61
Bauersachs, J. K., Fraccarollo, D., Ertl, G., Gretz, N., Wehling, M., & Christ, M. (2000) · Circulation · doi:10.1161/01.cir.102.19.2325 · Cited by 61
du Cailar, G., Fesler, P., Ribstein, J., & Mimran, A. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.159277 · Cited by 59
Ménard, J., Rigel, D. F., Watson, C. E., Jeng, A. Y., Fu, F., Beil, M. E., Liu, J., Chen, W., Hu, C.-W., Leung-Chu, J., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0340-9 · Cited by 58
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives
Epstein, M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg339 · Cited by 60
Heart Failure: A Class Review of Pharmacotherapy.
Shah, A. A., Gandhi, D., Srivastava, S., Shah, K. J., & Mansukhani, R. P. (2017) · PubMed Central · Cited by 55
Inhibition of the renin–angiotensin system and target organ protection
Iwanami, J., Mogi, M., Iwai, M., & Horiuchi, M. (2009) · Hypertension Research · doi:10.1038/hr.2009.5 · Cited by 56
Antihypertensive effect of the bovine casein-derived peptide Met-Lys-Pro
Yamada, A., Sakurai, T., Ochi, D., Mitsuyama, E., Yamauchi, K., & Abe, F. (2014) · Food Chemistry · doi:10.1016/j.foodchem.2014.09.098 · Cited by 55
Rationale for the Use of Aldosterone Antagonists in Congestive Heart Failure
Rocha, R., & Williams, G. H. (2002) · Drugs · doi:10.2165/00003495-200262050-00001 · Cited by 54
Crompton, M., Ferguson, J., Ramnath, R. D., Onions, K. L., Ogier, A. S., Gamez, M., Down, C. J., Skinner, L., Wong, K., Dixon, L. K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.154164 · Cited by 52
Kurrelmeyer, K. M., Ashton, Y. P., Xu, J., Nagueh, S. F., Torre‐Amione, G., & Deswal, A. M. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.05.010 · Cited by 52
Meredith, E. L., Ksander, G. M., Monovich, L. G., Papillon, J. P. N., Liu, Q., Miranda, K., Morris, P., Rao, C., Burgis, R., Capparelli, M. P., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400324c · Cited by 51
Hara, Y., Hamada, M., Shigematsu, Y., Suzuki, M., Kodama, K., Kuwahara, T., Hashida, H., Ikeda, S., Ohtsuka, T., Hiasa, G., et al. (2000) · Japanese Circulation Journal-english Edition · doi:10.1253/jcj.64.365 · Cited by 51
Potential Applications of Food Derived Bioactive Peptides in Management of Health
Dhaval, A., Yadav, N., & Purwar, S. (2016) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-016-9514-z · Cited by 52
Imagawa, K., Okayama, S., Takaoka, M., Kawata, H., Naya, N., Nakajima, T., Horii, M., Uemura, S., & Saito, Y. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000197539.12685.f5 · Cited by 50
Ravis, W. R., Reid, S. R., Sica, D. A., & Tolbert, D. S. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005275894 · Cited by 49
Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics
Costello‐Boerrigter, L. C., Boerrigter, G., & Burnett, J. C. J. (2003) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00181-5 · Cited by 47
Mineralocorticoid Antagonism and Diabetic Kidney Disease
Lytvyn, Y., Godoy, L. C., Scholtes, R. A., van Raalte, D. H., & Cherney, D. Z. I. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1123-8 · Cited by 48
Kobayashi, M., Pitt, B., Ferreira, J. P., Rossignol, P., Girerd, N., & Zannad, F. M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf225 · Cited by 51
Nagase, M. (2010) · Clinical and Experimental Nephrology · doi:10.1007/s10157-010-0298-8 · Cited by 43
Suzuki, H., Kanno, Y., Kaneko, K., Kaneko, M., Kotaki, S., Mimura, T., & Takane, H. (2004) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1526-0968.2004.00142.x · Cited by 43
Angiotensin converting enzyme inhibitors. I. Pharmacology
Kostis, J. B. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90747-8 · Cited by 43
Dual inhibition of the renin system by aliskiren and valsartan
Birkenhäger, W. H., & Staessen, J. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61099-x · Cited by 41
Self-citationEplerenone: A Selective Aldosterone Blocker
Stier, C. T. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00114.x · Cited by 42
Importance of Neuroendocrine Activation in Chronic Heart Failure. Impact on Treatment Strategies
Swedberg, K. B. (2000) · European Journal of Heart Failure · doi:10.1016/s1388-9842(00)00102-1 · Cited by 42
Ruilope, L. M., Agarwal, R., Chan, J. C. N., Cooper, M. E., Gansevoort, R. T., Haller, H. G., Remuzzi, G., Rossing, P. R., Schmieder, R. E., Nowack, C., et al. (2014) · American Journal of Nephrology · doi:10.1159/000371497 · Cited by 41
The Forgotten Antiproteinuric Properties of Diuretics
Trujillo, H., Caravaca‐Fontán, F., Caro, J., Morales, E., & Praga, M. (2021) · American Journal of Nephrology · doi:10.1159/000517020 · Cited by 41
Iwashima, Y., Horio, T., Kuroda, S., Takishita, S., & Kawano, Y. (2002) · Hypertension Research · doi:10.1291/hypres.25.49 · Cited by 40
Aldosterone antagonists for people with chronic kidney disease requiring dialysis
Hasegawa, T., Nishiwaki, H., Ota, E., Levack, W., & Noma, H. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013109.pub2 · Cited by 38
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy
Zannad, F. M. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90243-6 · Cited by 39
Aldosterone as a target in congestive heart failure.
Rajagopalan, S., & Pitt, B. (2003) · The Medical clinics of North America · doi:10.1016/s0025-7125(02)00183-9 · Cited by 38
Aldosterone and Aldosterone Antagonism in Cardiovascular Disease
Stier, C. T., Koenig, S., Lee, D. Y., Chawla, M. K., & Frishman, W. H. (2003) · Heart Disease · doi:10.1097/01.hdx.0000061698.20666.aa · Cited by 38
Metadata
- Authors
- STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A.
- ORCID
- STAESSEN, J.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 1981-12-01
- Volume
- 91
- Issue
- 3
- Pages
- 457-465
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W1971680322
- Cited by
- 339
- References
- 0
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 10 · 2014: 20 · 2013: 7 · 2012: 14
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- aldosterone, captopril, ACE inhibitors, hypertension, plasma renin activity, renin-angiotensin system, long-term drug therapy, hypotension
- MeSH terms
- Adult, Aldosterone, Angiotensin II, Captopril, Depression, Chemical, Female, Humans, Hypertension, Male, Middle Aged, Proline, Renin, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
